Gilead Sciences, Inc. (GILD), a US-based biopharmaceutical company, Thursday reported its financial results for the second quarter of 2025 ended on June 30.
The net income of $1.9 billion or $1.56 per share in the second quarter, an increase from $1.61 billion or $1.29 per share in the same quarter last year.
The company reported adjusted net income of $2.521 billion or $2.01 per share in the three month period, a slight increase from $2.519 billion or $2.01 per share last year.
GILD reported operating income of $2.4 billion in three month period, a slight decrease from $2.6 in the same quarter last year.
The company net sales of $7.1 billion in the second quarter, an increase from $6.9 billion in same quarter last year.
For full-year 2025, Gilead expects product sales between $28.3 billion and $28.7 billion, compared to the prior guidance of $28.2 billion to $28.6 billion. Product sales excluding Veklury are projected at $27.3 billion to $27.7 billion, up from the previous estimate of $26.8 billion to $27.2 billion. Veklury sales are forecast at $1.0 billion, down from the earlier projection of $1.4 billion.
The company anticipates diluted EPS in the range of $5.85 to $6.15, versus the prior $5.65 to $6.05, and non-GAAP diluted EPS between $7.95 and $8.25, compared to the earlier $7.70 to $8.10. Additional details and reconciliations between GAAP and non-GAAP figures for the 2025 guidance are provided in the accompanying tables. The outlook remains subject to various risks and uncertainties.
Thursday, GILD closed at $110.28 with no change and is currently trading at $113.51, up 2.93%, on the NasdaqGS.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.